Paper Details

Paper Title

Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.

Paper Journal Title

Cancer Chemother Pharmacol

Paper Citation Count

Paper Publication Year

2017

Bio Mention

Mesh Descriptor

Author Name	Affiliation
Anna McGlothlin	Eli Lilly and Co.
Anna McGlothlin

Column Actions